1. health and fitness
2. disease

2
Non-typhoidal Salmonella
in Children: Microbiology,
Epidemiology and Treatment
Gabrielle M. Haeusler and Nigel Curtis
Abstract
Non-typhoidal Salmonellae (NTS) are an important cause of infectious
diarrhoea world-wide. In the absence of immune deficiency, gastroenteritis caused by NTS is usually mild, self limiting and rarely requires intervention. NTS are also an important cause of invasive disease, particularly
in developing countries, likely secondary to the high prevalence of coexisting malnutrition, malaria and HIV infection. This review provides an
overview of the microbiology, epidemiology and pathogenesis of NTS,
and compares recommendations for the treatment of NTS gastroenteritis
in children.
2.1 Introduction
Non-typhoidal Salmonellae (NTS) are an important cause of infectious diarrhoea world-wide. In
the absence of immune deficiency, gastroenteritis caused by NTS is usually mild, self limiting
and rarely requires intervention. NTS are also
an important cause of invasive disease, particularly in developing countries, likely secondary to
N. Curtis ()
Department of Paediatrics, The University of Melbourne;
Infectious Diseases Unit, The Royal Children’s Hospital
Melbourne; Infectious Diseases & Microbiology
Research Group, Murdoch Children’s Research Institute,
Parkville, Australia
e-mail: [email protected]
G. M. Haeusler
Infectious Diseases Unit, The Royal Children’s Hospital
Melbourne, Parkville, Australia
e-mail: [email protected]
the high prevalence of co-existing malnutrition,
malaria and HIV infection. Antibiotic treatment
of NTS gastroenteritis has been the subject of a
meta-analysis, but questions regarding exactly
which patients should be treated and the optimal
regimen remain unanswered. This review provides an overview of the microbiology, epidemiology and pathogenesis of NTS, and compares
recommendations for the treatment of NTS gastroenteritis in children.
2.2 Classification and Microbiology
The genus Salmonella belongs to the family of
Enterobacteraciae. Salmonella are separated
into two species, Salmonella enterica and Salmonella bongori (previously classified as subsp.
V.), with the former being further classified into
six subspecies (I, S. enterica subsp. enterica; II,
N. Curtis et al. (eds.), Hot Topics in Infection and Immunity in Children IX,
Advances in Experimental Medicine and Biology 764, DOI 10.1007/978-1-4614-4726-9_2,
© Springer Science+Business Media New York 2013
13
14
G. M. Haeusler and N. Curtis
Table 2.1 Number of serotypes in each subspecies.
(Based on data from Grimont et al. [1])
Species
Subspecies
Number of
serotypes
1,531
enterica (I)
505
salamae (II)
99
arizonae (IIIa)
336
diarizonae (IIIb)
73
houtenae (IV)
13
indica (VI)
22
Salmonella bongori (V) –
Total
2,579
Table 2.2 Examples of clinically significant Salmonella
serotypes and relevant clinical syndromes according to
serogroup. (Based on data from Grimont et al. [1])
Serogroup
Salmonella enterica
S. enterica subsp. salamae; IIIa, S. enterica
subsp. arizonae; IIIb, S. enterica subsp. diarizonae; IV, S. enterica subsp. houtenae; and VI,
S. enterica subsp. indica) [1]. While an alternative nomenclature describes the genus as a single
species, Salmonella choleraesuis, the Judicial
Commission of the International Committee on
the Systematics of the Prokaryotes supports the
two-species designation [2].
Salmonellae are motile, Gram negative, facultative anaerobic bacilli which rarely ferment
lactose [3]. Within the seven subspecies, more
than 2,500 serotypes (or serovars) have been
reported (Table 2.1) [1]. Salmonellae are classified according to antigenically diverse surface
antigens: polysaccharide O (somatic) antigens,
H (flagellar) antigens and Vi (capsular) antigens [3]. Agglutination reactions based on the
O-antigen are used by most clinical laboratories to divide Salmonella into serogroups which
include, but are not limited to, A, B, C1, C2, D
and E (Table 2.2) [1]. Strains in these six serogroups cause most of the NTS infections in
humans [4]. Formal serotyping, usually by reference laboratories, is required to differentiate
clinically significant serotypes as cross-reactivity
occurs. A detailed list of all currently recognised
Salmonella serotypes is available elsewhere [4].
Salmonella nomenclature and syntax is potentially confusing. An example of a correct Salmonella subspecies and serotype designation is
Salmonella enterica subspecies enterica serotype
Typhimurium. An accepted abbreviation of this
full taxonomic designation is Salmonella ser.
Serotype
examplea
A
B
Paratyphi A
Paratyphi B
Typhimurium
Heidelberg
C1
Paratyphi C
Choleraesuis
Virchow
C2
Newport
D1
Typhi
Enteritidis
Dublin
a All example serotypes are members
monella enterica subspecies enterica
Clinical
syndrome
Enteric fever
Enteric fever
NTS
NTS
Enteric fever
NTS
NTS
NTS
Enteric fever
NTS
NTS
of subspecies Sal-
Typhimurium (capitalised and not italicised) at
the first citation and subsequently Salmonella
Typhimurium [5].
Salmonella enterica subspecies enterica contains almost all the serotypes pathogenic for
humans [3]. Although many Salmonella serotypes exist, they can be broadly categorised as
typhoidal or non-typhoidal Salmonella (NTS)
depending on the clinical syndrome with which
they are predominantly associated (Table 2.2).
The typhoidal Salmonella include the S. enterica
subspecies enterica serotypes Typhi and Paratyphi A-C and typically cause systemic illness with
little or no diarrhoea. The much larger group of
NTS primarily induce acute, self-limiting gastroenteritis and is the focus of this review.
2.3 Epidemiology
In contrast to Salmonella Typhi and Salmonella
Paratyphi, which are rarely encountered outside endemic countries or in returned travellers,
NTS have a worldwide distribution. While the
true incidence is unknown, there are an estimated 93.8 million episodes and 155,000 deaths
each year attributable to NTS [6]. Data from the
World Health Organization (WHO) Global Foodborne Infections Network (GFN) indicate that
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
Salmonella Typhimurium and Salmonella ser.
Enteritidis account for nearly 80 % of all human
isolates reported globally [7].
Unlike Salmonella Typhi and Salmonella
Paratyphi, which have host specificity for
humans, NTS can be acquired from both animal
and humans. While poultry and eggs remain the
most common source of NTS, other animal reservoirs include reptiles, rodents, cats and dogs
[8, 9]. A case control study in the United States
found that up to 6 % of all sporadic NTS infections are attributable to reptile or amphibian contact [10].
Transmission is predominantly foodborne,
although other modes include consumption of
contaminated water, contact with infected animals and nosocomial exposure [4, 11]. The incubation for NTS gastroenteritis depends on the host
and the inoculum. It is usually 12–36 h, although
incubation periods of up to nearly 2 weeks have
been reported with certain strains [12–14].
2.4 Pathogenesis
Salmonellae are facultative intracellular pathogens that can survive within host macrophages
[15]. Unlike typhoidal salmonella, which have
the ability to evade the immune system, NTS
tend to induce a localised inflammatory response
in immunocompetent individuals, provoking a
large influx of polymorphonuclear leukoytes to
the intestinal lumen [16]. They can also colonise
small and large intestinal mucosa thus facilitating
prolonged periods of shedding [16].
Host factors predisposing to severe NTS infection include reduced gastric acidity, impaired cell
mediated and humoral immunity, and impaired
phagocytic function [16–18]. Salmonellae are
unable to survive at a gastric pH less than 2.5
[19] and patients with anatomical or functional
achlorhydria are at increased risk of developing
infection [20]. This is especially relevant to neonates where the combination of relative achlorhydria and frequent milk feeds may contribute to
their increased risk of NTS bacteraemia [21].
T-cell immunity is important in controlling
Salmonella as evidenced by increased suscep-
15
tibility to invasive NTS in HIV-infection [22,
23] and with corticosteroid use [24]. Children
with congenital defects in humoral immunity
including X-linked agammaglobulinaemia and
common variable immunodeficiency, are also
reported to have increased risk of persistent diarrhoea and invasive disease [16]. Impaired phagocytic function seen in chronic granulomatous
disease, haemoglobinopathies and malaria similarly increase the risk of invasive NTS infection
[16]. In addition, co-infection with Schistosoma
has been reported to cause prolonged and severe
illness due to altered macrophage function and
replication and survival of Salmonella within the
parasite [25].
2.5 Clinical Syndromes
Clinical manifestations of NTS can be broadly
divided into four groups:
1. Acute gastroenteritis
2. Extra-intestinal infection
3. Non-infectious sequelae
4. Salmonella carriage
2.5.1 Acute Gastroenteritis
Non-typhoidal salmonellae usually cause an
acute self-limiting gastroenteritis. In contrast
to typhoidal salmonella, infection with NTS
results in diarrhoea. This is profuse and usually non-bloody. Associated symptoms of fever,
abdominal cramping, nausea and vomiting may
also occur [4]. Diagnosis is confirmed on stool
culture. Fluid and electrolyte disturbances are the
most frequent complication of NTS gastroenteritis. Asymptomatic gastrointestinal infection can
also occur; however, given the rate of convalescent NTS excretion following acute infection, the
true incidence is unknown [26].
2.5.2 Extra-intestinal Infection
Overall, NTS bacteraemia is reported in up to
9 % of patients with acute gastroenteritis [27].
16
Choleraesuis, Heidelberg and Dublin are among
some of the serotypes more frequently associated with bacteraemia [28]. The incidence of
invasive disease is also modified by factors such
as age, region and underlying immune status.
Surveillance data from the United States showed
the incidence of invasive NTS was 7.8 cases per
100,000 in infants (aged less 1 year) compared
to less than 0.8 cases per 100,000 in older children [29]. Significant discordance in the burden
of invasive NTS between continents exists with
an estimated annual incidence of up to 388 per
100,000 children (aged less 5 years) in Africa
[30]. In this continent, the common invasive
serotypes are Typhimurium and Enteritidis. The
high prevalence of malaria in Africa, and its association with invasive NTS, has been postulated
as one reason for this difference [31]. Interestingly, recent studies in the Gambia, Kenya and
Tanzania have shown that the marked decline
in malaria prevalence has been paralleled by a
similar reduction in invasive NTS [32].
Bacteraemia may result in focal NTS infection
at any site, including the central nervous system
[33, 34]. Risk factors for focal disease are similar to those for bacteraemia [35], although focal
infections in non-immunocompromised children
are well described [36]. In one study, 7 of 12
(58 %) immunocompromised children developed
focal infection compared with 5 of 132 (4 %)
non-immunocompromised children [37].
Salmonella bacteraemia usually presents with
fever and/or sepsis. Persistent bacteraemia has
been documented in afebrile, well-appearing
infants with NTS gastroenteritis emphasising the
importance of blood cultures in this population
[38]. Conversely, bacteraemia has been described
in immunosuppressed patients without a history
of gastroenteritis [24]. Notably, in the African
setting, the majority of invasive NTS cases do not
have gastroenteritis.
Salmonella can be cultured from standard
blood culture media [3]. Positive urine culture
with Salmonella spp. may indicate bacteraemia
rather than faecal contamination [39]. Similar to
Salmonella Typhi, culture of bone marrow sam-
G. M. Haeusler and N. Curtis
ples may increase the diagnostic yield of NTS
[30, 40].
2.5.3 Non-infectious Sequelae
Non infectious sequelae following infectious
gastroenteritis are well described [41]. Reactive
arthritis after NTS infection has been reported
in up to 29 % of patients [42]. There are conflicting data on the association between antibiotic treatment for acute NTS gastroenteritis and
subsequent development of musculoskeletal
symptoms, some suggesting a decreased risk and
others an increased risk [42].
2.5.4 Salmonella Carriage
Salmonella carriage is defined as asymptomatic
excretion following acute infection and can be
divided into convalescent carriage and chronic
carriage.
2.5.4.1 Convalescent Carriage
Convalescent carriage occurs frequently after
symptomatic or asymptomatic NTS infection.
Fig. 2.1 shows the duration of excretion of NTS
in 13 studies according to age [43]. The median
duration of NTS excretion in children less than
5 years of age is 7 weeks, with 18 % remaining
culture positive at 6 months. Carriage is shorter
in older children with a median duration of 3–4
weeks with only 0.3 % remaining culture positive
at 6 months. In addition to younger age, factors
associated with prolonged duration of excretion
include symptomatic infection, treatment with
antibiotics and infection with strains other than
Salmonella Typhimurium (Fig. 2.2) [43]. Episodic excretion is not uncommon.
2.5.4.2 Chronic Carriage
Documented excretion of NTS for more than
1 year is defined as chronic carriage [44]. This
occurs in up to 2.6 % of children under 5 years of
age and 0.3 % of older children [43].
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
17
Fig. 2.1 Duration of
excretion of NTS by age
(by permission of Oxford
University Press). [43]
Fig. 2.2 Duration of
excretion of NTS by
serotype (by permission
of Oxford University
Press). [43]
2.6 Treatment
Recommendations for the treatment of acute
gastroenteritis due to NTS vary (Table 2.3). The
rationale for treatment of both acute NTS gastroenteritis and carriage will be the focus of the
remainder of this review. Recommendations for
the treatment of extra-intestinal complications of
NTS are available elsewhere [4].
Antibiotic agents with in vitro and in vivo activity against NTS include ampicillin/amoxicillin,
trimethoprim-sulfamethoxazole, tetracyclines,
third generation cephalosporins, macrolides
and fluoroquinolones. Aminoglycosides show
good in vitro activity but poor clinical efficacy
and are not recommended [9, 45]. Ciprofloxacin and other fluoroquinolones have previously
been restricted in children due an association
with arthropathy, first described in young beagles
[46]. However, a systematic review of the safety
of ciprofloxacin in children has found that musculoskeletal adverse effects are infrequent (risk
1.6 %, 95 % CI 0.9–2.6 %), generally mild and
usually reversible [47].
2.6.1 NTS Gastroenteritis
A Cochrane review of trials investigating antibiotic treatment of NTS concluded that there
was no evidence to support antibiotic therapy in
otherwise healthy children and adults with nonsevere diarrhoea [58]. It included 12 randomised
controlled trials (RCT) published before 1998,
of which only five reported on clinical outcomes
that were extractable for meta-analysis. Importantly, almost all trials excluded infants less than
6 weeks and patients with underlying disease and
18
G. M. Haeusler and N. Curtis
Table 2.3 Recommendations for the treatment of acute NTS gastroenteritis. (With duration of treatment and/or specified antibiotic choice when stated in source)
Source
Age < 3 months
Severe
infection
Immunocompromised
Chronic
Haemoglobinopa- GI
disease
thies
Other
Infectious diseases and paediatric reference books
Textbook of Pediatric
Infectious Diseases (Feigin
and Cherry) [48]
Forfar and Arneil’s Textbook of Pediatrics [49]
Evidence-based Pediatric
Infectious Diseases (Isaacs)
[50]
Principles and Practice
of Pediatric Infectious
Diseases (Long) [51]
Mandell, Douglas and
Bennett’s Principles and
Practice of Infectious
Diseases [4]
Nelson Textbook of Pediatrics [52]
Oski’s Principles and Practice of Pediatrics [53]
Red Book: 2009 Report of
the Committee on Infectious Diseases [12]
Infectious Diseases of
the Fetus and Newborn
(­Remington & Klein) [21]
Rudolph’s Pediatrics [54]
The Sanford Guide to Antimicrobial Therapy [45]
Yes, 5d
–
Yes, 5d
Yes, 5d
–
–
Yes
–
Yes
–
–
–
Yes, 5–7d
Yes,
5–7d
Malnourished,
5–7d
–
Yes
–
Yes, 5–7d Yes, 5–7d
Yes, 5–7d, ciprofloxacin or azithromycin (empiric)
and amoxicillin if
susceptible
Yes
–
Yes
–
–
–
Yes,
7–14d,
fluoroquinolone
Yes, 7–14d Yes, 7–14d –
–
Yes
–
Yes
Malnourished
Yes, as per
susceptibilities
–
Yes, 3–5d
–
–
Yes, as per Yes, as per Yes,
as per
susceptisusceptisusceptibilities
bilities
bilities
Yes, 3–5d –
–
–
Yes
Yes ( < 1y), 7–10d,
fluoroquinolone
–
Yesb,
7–10d,
fluoroquinolone
Yes, 2–3d
–
Yes, 7–14d
Other sources
IDSA Guidelines 2001 [55] Yes ( < 6m), 3–7d
Yes ( < 6m)
NICE guidelines: Diarrhoea and Vomiting Caused
by Gastroenteritis [56]
UpToDate [57]
Yes, 3–10d
a
b
Yes
Yes, 14d,
fluoroquinolone
Yes
–
Valvular heart
disease; joint
disease, 2–3d
–
Yes,
7–10d,
fluoroquinolone
–
–
–
Haemodialysis;
vascular aneurysm; prosthetic
joints, 7–10d,
fluoroquinolone
Yes, 3–7d Yes, minimum 14d
–
Yes
–
–
–
–
Valvular heart
disease, 3–7d
Malnourished
Yesa,
3–7d
Yes, minimum 14d
–
–
Yes, minimum 1d
Defined as high fever, severe diarrhoea ( > 9 stools per day), need for hospitalisation
Defined as hospitalised with fever and severe diarrhoea
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
severe illness. Five studies were in infants and
children ( n = 258), with only one study including infants less than 4 weeks [59–63]. The review
did not identify significant differences in length
of illness, diarrhoea or fever between any antibiotic regimen and placebo. Furthermore, although
antibiotics were associated with more negative
stool cultures during the first week of treatment,
clinical relapse was more common and there were
more cases of positive cultures at three weeks in
the antibiotic-treated group. Adverse drug reactions, including rash, gastrointestinal upset and
headache, were also more common in the antibiotic group [58]. Given the exclusion criteria,
these results can not be extrapolated to patients at
higher risk of severe and invasive infection.
Although the treatment of patients with risk
factors for invasive disease seems reasonable, a
benefit has not been documented in a RCT. This
paucity of data likely explains the discrepancies
in treatment recommendations between guidelines and reference books detailed in Table 2.3.
Despite this variability, recommendations for
the treatment of infants under 3–6 months of age
and immunocompromised patients are consistent
between all identified references. A 1988 consensus statement for the management of Salmonella
infections in the first year of life similarly recommends treatment in infants less than 3 months following a blood culture irrespective of the severity
of illness [64]. Other conditions where treatment
has been recommended, albeit less consistently,
include haemaglobinopathies, chronic gastrointestinal disease (for example inflammatory bowel
disease), severe infection, malnourished state and
vascular or joint disease.
Agents for treatment of NTS can be divided
into non-absorbable (colistin and neomycin),
absorbable (ampicillin, amoxicillin, tetracycline,
macrolide and trimethoprim-sulfamethoxazole)
and those with potent intra-cellular activity (fluoroquinolones) [58]. As Salmonellae are intracellular pathogens, it is postulated that the latter
may be more effective in treatment of this infection and is specifically recommended for treatment of immunocompromised patients in two
sources [4, 45]. The Cochrane review included
eight trials involving fluroquinolones [58]. Subgroup analysis showed no benefit of treatment
19
with fluoroquinolones, although negative stool
cultures in the first week of treatment were more
likely with fluroquinolone treatment compared
to other absorbable antibiotics. Consequently, as
there are insufficient data to recommend a particular agent, empiric treatment should be based
on local susceptibility data and modified according to susceptibility results.
The optimal duration of treatment of NTS
gastroenteritis has not been studied. Recommendations vary amongst sources between 3 and
14 days depending on the underlying condition
(Table 2.3). Of the trials included in the Cochrane
review, duration varied between 1 and 14 days,
with 5 days being the most common treatment
regimen. The authors commented that the two
studies with longer antibiotic treatment duration
(10 and 14 days) showed an apparent benefit of
antibiotics at 8–21 days [58]. Subsequent to this
review, a study reported that 10 days of ofloxacin
compared with 5 days resulted in earlier eradication of NTS without an increase in carriage [65].
However, this study was relatively small and did
not include a placebo arm.
Other trials have also been published since the
last Cochrane review update in 1999 with conflicting results [66, 67]. An updated meta-analysis is awaited [68].
2.6.2 Convalescent NTS Carriage
Treatment of convalescent NTS carriage in children has not been subject to RCT but is generally
not recommended (Table 2.4).
2.6.3 Chronic NTS carriage
There are no RCT investigating the treatment
of chronic NTS carriage in healthy children. In
adults with chronic carriage, norfloxacin and
azithromycin were no better than placebo in
eradicating carriage and were associated with
higher rates of re-infection and selection of drugresistant isolates in endemic areas [69]. However,
although antibiotics have been shown to prolong
NTS excretion, this paradoxical finding may only
20
G. M. Haeusler and N. Curtis
Table 2.4 Recommendations for treatment of convalescent and chronic NTS. (With duration of treatment and/or specified antibiotic choice when stated in source)
Source
Convalescent excretion
Infectious diseases and paediatric reference books
Textbook of Pediatric Infectious Diseases (Feigin –
and Cherry) [48]
Forfar and Arneil’s Textbook of Pediatrics [49]
Not recommended
Evidence-based Pediatric Infectious Diseases
Not recommended
(Isaacs) [50]
Principles and Practice of Pediatric Infectious
–
Diseases (Long) [51]
Mandell, Douglas and Bennett’s Principles and
‘Not recommended for
Practice of Infectious Diseases [4]
uncomplicated convalescent
excretion’
Nelson Textbook of Pediatrics [52]
–
Oski’s Principles and Practice of Pediatrics [53]
Not recommended
Red Book: 2009 Report of the Committee on
–
Infectious Diseases [12]
Infectious Diseases of the Fetus and Newborn
Not recommended for infants
(Remington & Klein) [21]
Rudolph’s Pediatrics [54]
–
The Sanford Guide to Antimicrobial Therapy [45] –
Other sources
IDSA Guidelines 2001 [55]
NICE Guideline: Diarrhoea and Vomiting Caused
by Gastroenteritis [56]
UpToDate [57]
Chronic carriage (> 1 year)
Not recommended
–
–
‘Treatment of persons with
asymptomatic carriage of NTS
is controversial’
–
Not recommended
Not recommended
–
–
–
–
–
–
–
–
Recommended for all
patients. Duration: 4–6 weeks;
fluoroquinolone
HIV infection: ‘consider suppressive prophylactic therapy if
failure to eradicate’
be relevant following treatment of acute NTS
infection. In the Cochrane review, only three trials included asymptomatic patients (7.2 % of all
participants) and separate data were not available
for subgroup analysis [58].
Treatment of chronic NTS carriage is recommended in one source, based on data for the
eradication of chronic Salmonella Typi and Paratyphi [57, 70] (Table 2.4). In patients with HIV
infection, prolonged ciprofloxacin (minimum 3
months) may also reduce NTS relapse [71] and
up to 6 months suppressive treatment is recommended for HIV-infected adolescents and adults
with recurrent NTS bacteraemia [72].
2.7 NTS and Pregnancy
Pregnancy does not appear to increase the risk
of maternal NTS infection. Screening of a large
cohort of pregnant women (30,471) at the time
of delivery detected NTS in only 60 (0.2 %), of
which 17 (28 %) were symptomatic [73]. Of the
60 babies born, only seven (11.7 %) excreted NTS
and five (8.3 %) had gastroenteritis. Transplacental infection can occur in the setting of maternal
NTS bacteraemia and is often lethal to the foetus
[74]. Transmission of NTS through breast milk
has also been described, including three nursery
outbreaks due to infected pooled milk [75]. More
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
21
Table 2.5 Infection control recommendations
Source
Recommendation
Infectious diseases and paediatric reference books
Textbook of Pediatric Infectious Diseases, Hospitalised patient: standard and contact precautions until stool
(Feigin and Cherry) [53]
cultures are negative. Surveillance cultures on all neonates in nursery
Forfar and Arneil’s Textbook of Pediatrics ‘No restriction of activities if stool is normal’
[49]
Evidence-based Pediatric Infectious
–
Diseases (Isaacs) [50]
Principles and Practice of Pediatric
Hospitalised patient: standard and contact precautions
Infectious Diseases (Long) [51]
Mandell, Douglas and Bennett’s Principles Hospitalised patient: standard and contact precautions
and Practice of Infectious Diseases [4]
Health care worker: exclusion until asymptomatic and passing formed
stool
Nelson Textbook of Pediatrics [52]
–
Oski’s Principles and Practice of Pediatrics –
[53]
Red Book: 2009 Report of the Committee
Hospitalised patient: Standard and contact precautions for diapered
on Infectious Diseases [12]
and incontinent children for duration of illness
Infectious Diseases of the Fetus and Newborn (Remington & Klein) [21]
Rudolph’s Pediatrics [54]
The Sanford Guide to Antimicrobial
Therapy [45]
Infection control sources
CDC: 2007 Guideline for Isolation Precautions [95]
NHMRC: Australian Guidelines for Prevention and Control of Infection in Healthcare
[96]
Other sources
IDSA Guideline 2001 [55]
NICE guideline: Diarrhoea and Vomiting
caused by Gastroenteritis [56]
UpToDate [57]
Child care: exclusion until diarrhoea resolves. Contacts do not require
stool culture. Exclude symptomatic contacts until diarrhoea resolves
Hospitalised neonate: standard and contact precautions. ‘When two
or more cases are recognized, environmental cultures, cultures of all
infants, cohorting, early discharge of infected infants, and thorough
cleaning of all possible fomites in the nursery and delivery rooms are
recommended. If cases continue to occur, the nursery should be closed
to further admissions’
–
–
Hospitalised patient: standard and contact precautions for diapered or
incontinent persons for duration of illness
Hospitalised patient: contact precautions for faecally incontinent
patients for duration of illness
Health care worker: exclusion until 24 h after symptoms have resolved
–
Childcare/school: exclusion until 48 h after symptoms have resolved
Healthcare workers: exclusion until diarrhoea resolves
Food handlers: as above
recently, outbreaks associated with formula feed
have been reported [76].
Treatment of asymptomatic maternal NTS
carriage is unlikely to be of benefit, but should
be considered for severe infection. There are no
guidelines for empiric treatment of neonates with
known maternal excretion. Due to the increased
risk of severe infection in this group, consideration should be given to screening and treatment,
as outlined previously, if NTS is detected in the
stool [77].
22
G. M. Haeusler and N. Curtis
2.8 Antibiotic Resistance
2.9 Infection Control
Antibiotic-resistant NTS are associated with
increased treatment failure and risk of invasive
disease [78]. Worldwide surveillance data has
demonstrated an overall increase in antibiotic
resistance among NTS, although significant geographical and serotype variability exist [79, 80].
The widespread use of antibiotics in food animals
has been implicated in the increasing prevalence
of antibiotic resistant NTS [81].
The European Centre for Disease Control (formally Enter-net) and the National Antimicrobial
Resistance Monitoring System (NARMS)
provide comprehensive surveillance data on
rates of NTS drug resistance in Europe and the
United States [82, 83]. Data from these studies,
as well as reports from middle to low income
countries, indicate high rates of ampicillin,
amoxicillin and trimethoprim-sulfamethoxazole resistance, particularly among the globally
prevalent serotypes Salmonella Enterididis and
Salmonella Typhimurium [82–84]. Of particular concern is the emergence of extended spectrum beta-lactamase (ESBL) genes in NTS [80],
as well as reports of carbapenemase-containing
NTS isolates [85, 86], both of which confer high
level antimicrobial resistance.
Fluoroquinolones and third generation cephalosporins are frequently used for the treatment
of NTS that are resistant to conventional antibiotics, although reports of increasing resistance to these second line agents are emerging
[80]. Isolates resistant to nalidixic acid are
frequently resistant to fluoroquinolones, and
this is a recommended screening test for ciprofloxacin resistance [3]. However, although
a study found the nalidixic acid disk diffusion
method was 100 % sensitive for the detection of
reduced ciprofloxacin susceptibility (defined as
MIC > 0.125 μg/ml) [87], there have been subsequent reports of isolates that are susceptible to
nalidixic acid but exhibit reduced susceptibility
to ciprofloxacin [88].
Outbreaks of NTS have been reported in neonatal units, paediatric wards and child care facilities [11, 89]. However, despite the frequency of
asymptomatic NTS excretion following acute
infection, the risk of transmission from asymptomatic health care workers to patients appears to
be small when strict adherence to hand hygiene
is observed [90]. Similarly, transmission from
asymptomatic food handlers is rare, with one survey identifying only 2 % of food handlers as the
source of 566 NTS outbreaks [91].
Methods to control the spread of Salmonella
include appropriate food preparation, water sanitation and strict hand hygiene. Most resources
recommend exclusion of children, health care
workers and food handlers from childcare/school
or work until 24–48 h after resolution of symptoms (Table 2.5). For symptomatic hospitalised
patients, standard and contact precautions are
recommended. There are also some non-randomised data that suggest the prophylactic use
of antibiotics (trimethoprim-sulfamethoxazole or
ciprofloxacin) in addition to strict barrier nursing, may control nosocomial Salmonella epidemics [92–94]. Confirmation of clearance of NTS is
generally not recommended.
Acknowledgements We wish to thank Steve M. Graham
for his helpful comments and suggestions.
References
1. Grimont PAD, Weill F (2007) Antigenic Formulae
of the Salmonella Serovars. 9th edn. Institut Pasteur,
Paris
2. Tindall BJ, Grimont PAD, Garrity GM, Euzeby JP
(2005) Nomenclature and taxonomy of the genus
Salmonella. Int J Syst Evol Microbiol 55:521–524
3. Nataro JP, Bopp CA, Fields PI, Kaper JB, Strockbine
NA (2011) Escherichia, Shigella, and Salmonella.
In: Versalovic J, Carroll KC, Funke G, Jorgensen JH,
Landry ML, Warnock DW (eds.). Manual of Clinical
Microbiology, 10th edn. ASM, Washington, DC, p
603–626
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
4. Pegues DA, Miller SI (2010) Salmonella Species, including Salmonella Typhi. In: Mandell GL,
Bennett JE, Dolin R (eds). Mandell, Douglas and
Bennett’s Principles and Practices of Infectious Diseases, 7th edn. Elsevier, Philadelphia, p 2887–2903
5. Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B (2000) Salmonella nomenclature. J Clin
Microbiol 38:2465–2467
6. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk
M, O’Brien SJ et al (2010) The global burden of
nontyphoidal Salmonella gastroenteritis. Clin Infect
Dis 50:882–889
7. Vieira A, Jensen AR, Pires SM, Karlsmose S,
Wegener HC, Wong DLF (2009) WHO Global
Foodborne Infections Network Country Databank—a resource to link human and non-human
sources of Salmonella. Int Soc Vet Epidemiol Econ
643:512–517
8. Braden CR (2006) Salmonella enterica serotype
Enteritidis and eggs: a national epidemic in the
United States. Clin Infect Dis 43:512–517
9. Hohmann EL (2001) Nontyphoidal salmonellosis.
Clin Infect Dis 32:263–269
10. Mermin J, Hutwagner L, Vugia D, Shallow S,
Daily P, Bender J et al (2004) Reptiles, amphibians, and human Salmonella infection: a populationbased, case-control study. Clin Infect Dis 38(Suppl
3):S253–261
11. Weikel CS, Guerrant RL (1985) Nosocomial salmonellosis. Infection Control: IC 6:218–220
12. AAP (2006) Salmonella Infections. In: Pickering
LK, Baker CJ, Kimberlin DW, Long SS (eds). Red
Book: 2009 Report of the Commitee on Infectious
Diseases, 28th edn. American Academy of Pediatrics, Elk Grove Village, p 584–588
13. Blaser MJ, Newman LS (1982) A review of human
salmonellosis: I. Infective dose. Rev Infect Dis
4:1096–1106
14. Seals JE, Parrott PL, McGowan JE, Jr., Feldman RA
(1983) Nursery salmonellosis: delayed recognition
due to unusually long incubation period. Infection
Control: IC 4:205–208
15. Garcia-del Portillo F (2001) Salmonella intracellular proliferation: where, when and how? Microbes
Infect 3:1305–311
16. Dougan G, John V, Palmer S, Mastroeni P
(2011) Immunity to salmonellosis. Immunol Rev
240:196–210
17. Gondwea EN, Molyneuxa ME, Goodallc M, Graham SM, Mastroenig P, Draysonc MT et al (2010)
Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. PNAS
107:3070–3075
18. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, White SA et al (2008) The
neglected role of antibody in protection against nontyphoidal salmonella bacteremia in African children.
J Clin Invest 118:1553–1562
23
19. Tennant SM, Hartland EL, Phumoonna T, Lyras
D, Rood JI, Robins-Browne RM et al (2008) Influence of gastric acid on susceptibility to infection
with ingested bacterial pathogens. Infect Immun
76:639–645
20. Buchin PJ, Andriole VT, Spiro HM (1980) Salmonella infections and hypochlorhydria. J Clin Gastroenterol 2:133–138
21. O’Ryan ML, Nataro JP, Cleary TG (2011) Microorganisms Responsible for Neonatal Diarrhea. In:
Remington JS, Klein JO, Wilson CB, Nizet V, Maldonado Y (eds). Remington: Infectious Diseases of
the Fetus and Newborn, 7th edn. Elsevier, Philadelphia, p. 359–418
22. Moir S, Fauci AS (2010) Immunology. Salmonella
susceptibility. Science 328:439–440 (New York,
NY)
23. Celum CL, Chaisson RE, Rutherford GW, Barnhart
JL, Echenberg DF (1987) Incidence of salmonellosis
in patients with AIDS. J Infect Dis 156:998–1002
24. Ramos JM, Garcia-Corbeira P, Aguado JM, Arjona
R, Ales JM, Soriano F (1994) Clinical significance
of primary vs. secondary bacteremia due to nontyphoid Salmonella in patients without AIDS. Clin
Infect Dis 19:777–780
25. Abruzzi A, Fried B (2011) Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Adv Parasitol 77:1–85
26. Jertborn M, Haglind P, Iwarson S, Svennerholm
AM (1990) Estimation of symptomatic and asymptomatic Salmonella infections. Scand J Infect Dis
22:451–455
27. Mandal BK, Brennand J (1988) Bacteraemia in
salmonellosis: a 15 year retrospective study from
a regional infectious diseases unit. BMJ 297:1242–
1243 (Clinical research ed)
28. Jones TF, Ingram LA, Cieslak PR, Vugia DJ, TobinD’Angelo M, Hurd S et al (2008) Salmonellosis outcomes differ substantially by serotype. J Infect Dis
198:109–114
29. Vugia DJ, Samuel M, Farley MM, Marcus R, Shiferaw B, Shallow S et al (2004) Invasive Salmonella
infections in the United States, FoodNet, 1996–
1999: incidence, serotype distribution, and outcome.
Clin Infect Dis 38(Suppl 3):S149–156
30. Gordon MA (2011) Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis. Curr Opin Infect Dis 24:484–489
31. Graham SM (2010) Nontyphoidal salmonellosis in
Africa. Curr Opin Infect Dis 23:409–414
32. Scott AJ, Berkley JA, Mwangi I, Ochola L, Uyoga
S, Macharia A et al (2011) Relation between falciparum malaria and bacteraemia in Kenyan children:
a population–based, case-control study and a longitudinal study. Lancet 378:1316–1323
33. Schutze GE, Schutze SE, Kirby RS (1997) Extraintestinal salmonellosis in a children’s hospital. Pediatr
Infect Dis J 16:482–485
24
34. Owusu-Ofori A, Scheld WM (2003) Treatment
of Salmonella meningitis: two case reports and a
review of the literature. Int J Infect Dis 7:53–60
35. Sirinavin S, Jayanetra P, Lolekha S, Layangkul T
(1988) Predictors for extraintestinal infection in
Salmonella enteritis in Thailand. Pediatr Infect Dis
J 7:44–48
36. Galanakis E, Bitsori M, Maraki S, Giannakopoulou C, Samonis G, Tselentis Y (2007) Invasive
non-typhoidal salmonellosis in immunocompetent
infants and children. Int J Infect Dis 11:36–39
37. Zaidi E, Bachur R, Harper M (1999) Non-typhi Salmonella bacteremia in children. Pediatr Infect Dis J
18:1073–1077
38. Katz BZ, Shapiro ED (1986) Predictors of persistently positive blood cultures in children with
“occult” Salmonella bacteremia. Pediatr Infect Dis
5:713–714
39. Ramos JM, Aguado JM, Garcia-Corbeira P, Ales
JM, Soriano F (1996) Clinical spectrum of urinary
tract infections due on nontyphoidal Salmonella species. Clin Infect Dis 23:388–390
40. Gasem MH, Keuter M, Dolmans WMV, Van Der
Ven-Jongekrijg J, Djokomoeljanto R, Van Der
Meer JWM (2003) Persistence of Salmonellae in
blood and bone marrow: randomized controlled
trial comparing ciprofloxacin and chloramphenicol
treatments against enteric fever. Antimicrob Agents
Chemother 47:1727–1731
41. Ternhag A, Torner A, Svensson A, Ekdahl K, Giesecke J (2008) Short–and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis
14:143–148
42. Arnedo-Pena A, Beltran-Fabregat J, Vila-Pastor B,
Tirado-Balaguer MD, Herrero–Carot C, BellidoBlasco JB et al (2010) Reactive arthritis and other
musculoskeletal sequelae following an outbreak of
Salmonella hadar in Castellon, Spain. J Rheumatol
37:1735–1742
43. Buchwald DS, Blaser MJ (1984) A review of human
salmonellosis: II. Duration of excretion following
infection with nontyphi Salmonella. Rev Infect Dis
6:345–356
44. Corrado ML, DuPont HL, Cooperstock M, Fekety R,
Murray DM (1992) Evaluation of new anti-infective
drugs for the treatment of chronic carriage of Salmonella. Infectious Diseases Society of America
and the Food and Drug Administration. Clin Infect
Dis 15(Suppl 1):S259–262
45. Gilbert DN, Moellering RC, Eliopoulis GM, Saag
MS (2011) The Sanford Guide to Antimicrobial
Therapy, 41st edn
46. Ingham B, Brentnall DW, Dale EA, McFadzean JA
(1977) Arthropathy induced by antibacterial fused
N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett
1:21–26
47. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I (2011) Ciprofloxacin safety in paediatrics: a
systematic review. Arch Dis Child 96:874–880
G. M. Haeusler and N. Curtis
48. Pickering LK (2009) Approach to Patients with
Gastrointestinal Tract Infections and Food Poisoning. In: Feigin RD, Cherry J, Demmler-Harrison
G, Kaplan S (eds). Textbook of Pediatric Infectious
Diseases. Elsevier, Philadelphia, p 621–653
49. Graham SM (2008) Salmonellosis. In: McIntosh
N, Helms P, Smyth R, Logan S (eds). Forfar and
Arneil’s Textbook of Pediatrics, 7th edn. Elsevier,
Philadelphia, p 1246–1249
50. Isaacs D (2007) Gastrointestinal infections. In:
Elliot E, Gilbert R, Moyer V, Pichichero M (eds).
Evidence-based Pediatric Infectious Diseases.
Blackwell Publishing, United Kingdom, p 74–101
51. Reller ME (2009) Salmonella Species. In: Long SS,
Pickering LK, Prober C (eds). Principles and Practice of Pediatric Infectious Diseases, 3rd edn. Elsevier, Philadelphia, p 812–817
52. Bhutta ZA (2011) Salmonella. In: Kliegman RM,
Stanton BMD, St Geme J, Schor N, Behrman RE
(eds). Nelson Textbook of Pediatrics, 19th edn. Elsevier, Philadelphia, p 948–958
53. Pickering LK (2006) Salmonella Infections. In:
McMillan JA, Feigin RD, DeAngelis D, Jones MD
(eds). Oski’s Pediatrics: Principles and Practice, 4th
edn. Lippincott Williams and Wilkins, Philadelphia,
p 1112–1116
54. Pavia AT (2011) Salmonella, Shigella, and Escherichia coli. In: Rudolph C, Rudolph A, Lister G,
First L, Gershon A (eds). Rudolph’s Pediatrics, 22nd
edn. McGraw Hill, New York
55. Guerrant RL, Van Gilder T, Steiner TS, Thielman
NM, Slutsker L, Tauxe RV et al (2001) Practice
guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331–351
56. (2009) Diarrhoea and vomiting caused by gastroenteritis: diagnosis, assessment and management in
children younger than 5 years. RCOG, London
57. Hohmann EL (2012) Approach to the patient with
nontyphoidal Salmonella in a stool culture. In:
Baron EL (ed). UpToDate, Waltham
58. Sirinavin S, Garner P (2000) Antibiotics for treating
salmonella gut infections. Cochrane Database Syst
Rev (Online):CD001167
59. Garcia de Olarte D, Hugo TS, Nancy AO, Nelson
JD, Haltalin KC (1974) Treatment of Diarrhea in
Malnourished Infants and Children: A Double-Blind
Study Comparing Ampicillin and Placebo. Am J Dis
Child 127:379–388
60. Nelson JD, Kusmiesz H, Jackson LH, Woodman
E (1980) Treatment of Salmonella gastroenteritis
with ampicillin, amoxicillin, or placebo. Pediatrics
65:1125–1130
61. Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD
(1972) Treatment of Acute Diarrhea in Outpatients:
Double-Blind Study Comparing Ampicillin and Placebo. Am J Dis Child 124:554–561
62. Kazemi M, Gumpert TG, Marks MI (1973) A controlled trial comparing sulfametboxazole–trimethoprim, ampicillin, and no therapy in the treatment
2 Non-typhoidal Salmonella in Children: Microbiology, Epidemiology and Treatment
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
of salmonella gastroenteritis in children. J Pediatr
83:646–650
Macdonald WB, Friday F, McEacharn M (1954) The
Effect of Chloramphenicol in Salmonella Enteritis
of Infancy. Arch Dis Child 29:238–241
Geme JW, 3rd, Hodes HL, Marcy SM, Pickering
LK, Rodriguez WJ, McCracken GH, Jr. et al (1988)
Consensus: management of Salmonella infection in
the first year of life. Pediatr Infect Dis J 7:615–621
Voltersvik P, Halstensen A, Langeland N, Digranes
A, Peterson LE, Rolstad T et al (2000) Eradication
of non-typhoid salmonellae in acute enteritis after
therapy with ofloxacin for 5 or 10 days. J Antimicrob Chemother 46:457–459
Stoycheva MV, Murdjeva MA (2006) Antimicrobial
therapy of salmonelloses–current state and perspectives. Folia Med (Plovdiv) 48:5–10
Tsai MH, Huang YC, Lin TY, Huang YL, Kuo CC,
Chiu CH (2011) Reappraisal of parenteral antimicrobial therapy for nontyphoidal Salmonella
enteric in­fection in children. Clin Microbiol Infect
17:300–305
Onwuezobe IA, Oshun PO (2008) Antbiotics
for treating nontyphoidal Salmonella diarrhoea.
Cochrane Database Syst. Rev
Sirinavin S, Thavornnunth J, Sakchainanont
B, Bangtrakulnonth A, Chongthawonsatid S,
Junumporn S (2003) Norfloxacin and azithromycin
for treatment of nontyphoidal salmonella carriers.
Clin Infect Dis 37:685–691
Zavala Trujillo I, Quiroz C, Gutierrez MA, Arias J,
Renteria M (1991) Fluoroquinolones in the treatment of typhoid fever and the carrier state. Eur J Clin
Microbiol Infect Dis 10:334–341
Nelson MR, Shanson DC, Hawkins DA, Gazzard
BG (1992) Salmonella, Campylobacter and Shigella
in HIV-seropositive patients. AIDS (London, England) 6:1495–1498
Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau
A, Masur H et al (2009) Guidelines for prevention
and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations
from CDC, the National Institutes of Health, and
the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep
58:1–207, (quiz CE1–4)
Roberts C, Wilkins EG (1987) Salmonella screening
of pregnant women. J Hosp Infect 10:67–72
Schloesser RL, Schaefer V, Groll AH (2004) Fatal
transplacental infection with non–typhoidal Salmonella. Scand J Infect Dis 36:773–774
Cooke FJ, Ginwalla S, Hampton MD, Wain J, RossRussell R, Lever A et al (2009) Report of neonatal
meningitis due to Salmonella enterica serotype Agona
and review of breast milk-associated neonatal Salmonella infections. J Clin Microbiol 47:3045–3049
Cahill SM, Wachsmuth K, Costarrica M, Embarek
P (2008) Powdered Infant Formula as a Source of
Salmonella Infection in Infants. Clin Infect Dis
46:268–273
25
77. Van Der Klooster JM, Roelofs HJ (1997) Management of Salmonella infections during pregnancy and
puerperium. Neth J Med 51:83–86
78. Varma JK, Molbak K, Barrett TJ, Beebe JL, Jones
TF, Rabatsky-Ehr T et al (2005) Antimicrobial–
resistant nontyphoidal Salmonella is associated with
excess bloodstream infections and hospitalizations.
J Infect Dis 191:554–561
79. Su L-H, Chiu C-H, Chu C, Ou JT (2004) Antimicrobial resistance in nontyphoid Salmonella serotypes:
a global challenge. Clin Infect Dis 39:546–551
80. Parry CM, Threlfall EJ (2008) Antimicrobial resistance in typhoidal and nontyphoidal salmonellae.
Curr Opin Infect Dis 21:531–538
81. Angulo FJ, Johnson KR, Tauxe RV, Cohen ML
(2000) Origins and consequences of antimicrobialresistant nontyphoidal Salmonella: implications for
the use of fluoroquinolones in food animals. Microb
Drug Resist (Larchmont, NY) 6:77–83
82. Crump JA, Medalla FM, Joyce KW, Krueger AL,
Hoekstra RM, Whichard JM et al (2011) Antimicrobial resistance among invasive nontyphoidal
Salmonella enterica isolates in the United States:
National Antimicrobial Resistance Monitoring System, 1996–2007. Antimicrob Agents Chemother
55:1148–1154
83. Meakins S, Fisher IST, Berghold C, Gerner-Smidt
P, Tschape H, Cormican M et al (2008) Antimicrobial drug resistance in human nontyphoidal Salmonella isolates in Europe 2000–2004: a report from
the Enter-net International Surveillance Network.
Microb Drug Resist (Larchmont, NY) 14:31–35
84. Reddy EA, Shaw AV, Crump JA (2010) Communityacquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis
10:417–432
85. Nordmann P, Poirel L, Mak JK, White PA, McIver
CJ, Taylor P (2008) Multidrug-resistant Salmonella
strains expressing emerging antibiotic resistance
determinants. Clin Infect Dis 46:324–325
86. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM (2003) Imipenem
resistance in a Salmonella clinical strain due to
plasmid-mediated class A carbapenemase KPC-2.
Antimicrob Agents Chemother 47:1297–1300
87. Hakanen A, Kotilainen P, Jalava J, Siitonen A,
Huovinen P (1999) Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol
37:3572–3577
88. Hakanen AJ, Lindgren M, Huovinen P, Jalava J,
Siitonen A, Kotilainen P (2005) New quinolone resistance phenomenon in Salmonella enterica: nalidixic
acid-susceptible isolates with reduced fluoroquinolone susceptibility. J Clin Microbiol 43:5775–5778
89. Chorba TL, Meriwether RA, Jenkins BR, Gunn RA,
MacCormack JN (1987) Control of a non-foodborne
outbreak of salmonellosis: day care in isolation. Am
J Public Health 77:979–981
26
90. Tauxe RV, Hassan LF, Findeisen KO, Sharrar RG,
Blake PA (1988) Salmonellosis in nurses: lack of
transmission to patients. J Infect Dis 157:370–373
91. (1987) Food handlers and salmonella food poisoning Lancet 2:606–607
92. Kassis I, Dagan R, Chipman M, Alkan M, Simo A,
Gorodischer R (1990) The use of prophylactic furazolidone to control a nosocomial epidemic of multiply resistant Salmonella typhimurium in pediatric
wards. Pediatr Infect Dis J 9:551–555
93. Dyson C, Ribeiro CD, Westmoreland D (1995)
Large scale use of ciprofloxacin in the control of a
Salmonella outbreak in a hospital for the mentally
handicapped. J Hosp Infect 29:287–296
G. M. Haeusler and N. Curtis
94. Linnemann CC, Jr., Cannon CG, Staneck JL,
McNeely BL (1985) Prolonged hospital epidemic
of salmonellosis: use of trimethoprim-sulfamethoxazole for control. Infection control: IC 6:221–225
95. Siegel JD, Rhinehart E, Jackson M, Chiarello L
(2007) Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare
Settings. Healthcare Infection Control Practices
Advisory Committee (HICPAC)
96. NHMRC (2010) Australian Guidelines for the Prevention and Control of Infection in Healthcare.
Commonwealth of Australia 1–262
http://www.springer.com/978-1-4614-4725-2